logo
Plus   Neg
Share
Email

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

Mylan Inc. (MYL) and Pfizer Inc. (PFE) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health... The Coca-Cola Company (KO) reported that its first-quarter comparable earnings per share from continuing operations grew 8% year-over-year to $0.47. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.46 for the quarter. Analysts' estimates typically exclude special items. Net income from continuing operations increased 12% to $1.33 billion. Earnings per share from continuing operations rose 13% to $0.31.
Follow RTT